Akums Drugs Guides Full-Year EBITDA Margins At 14% To 15% Following Strong Q1

Market snapshot: Akums Drugs and Pharmaceuticals Limited has provided positive operational guidance for FY27, maintaining its full-year EBITDA margin outlook at 14% to 15%. This guidance is supported by a robust Q1 FY27 performance where EBITDA margins reached 14.97%.

Data Snapshot

• Operating revenue grew 13.92% year-on-year to ₹1,166.63 crore in Q1 FY27.
• Consolidated profit after tax surged 57.55% year-on-year to ₹100.01 crore in Q1 FY27.
• EBITDA margin expanded by 238 basis points year-on-year to reach 14.97% in Q1 FY27.
• Contract Development and Manufacturing Operations (CDMO) segment revenue increased 18.55% year-on-year to ₹964.21 crore.

What's Changed

• Consolidated EBITDA margins expanded to 14.97% in Q1 FY27, up from 12.6% in Q1 FY26.
• Operating revenue increased to ₹1,166.63 crore in Q1 FY27, representing a 13.92% year-on-year growth from ₹1,024 crore.

Key Takeaways

• Full-year EBITDA margin guidance remains solid at 14% to 15%, with upward bias.
• Core CDMO segment is exhibiting robust volume growth, expected in double digits for the full year.
• API segment is on track for EBITDA breakeven by February or March 2027 (end of FY27).

SAHI Perspective

Akums' strong performance in Q1 FY27 provides substantial credibility to its FY27 margin guidance. Operating leverage in the CDMO business is playing out as expected, and the targeted turnaround in the API segment should alleviate a historical drag on overall profitability.

Market Implications

The robust CDMO growth suggests a healthy domestic pharmaceutical demand environment. Strategic expansion into higher-margin wellness and cosmetics lines will likely support valuation rerating.

Trading Signals

Market Bias: Bullish

Strong operating results in Q1 FY27 with EBITDA margins at 14.97% back the management's full-year guidance of 14% to 15% and support a positive near-term outlook.

Overweight: Pharmaceutical CDMO, Healthcare

Trigger Factors:

• Sustained double-digit volume growth in CDMO
• Turnaround in API segment profitability by March 2027

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian CDMO sector continues to benefit from supply chain diversification and outsourcing trends. Stricter implementation of regulatory standards like Schedule M is driving consolidated market share toward larger players like Akums.

Key Risks to Watch

• Pricing pressure and volatility in key API molecules.
• Margin compression in the domestic branded formulations segment due to increased field-force investments.

Recent Developments

Akums announced the acquisition of Oriflame India's manufacturing business on August 10, 2026, to expand into skincare, cosmetics, and wellness segments. A CRISIL monitoring report released around the same time verified the full utilization of the ₹642.18 crore IPO proceeds.

Closing Insight

Akums is transitioning from a domestic-focused CDMO player into a diversified formulation and wellness manufacturer, with clear near-term visibility on margin improvements.

High Performance Trading with SAHI.